Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institutes of Health Clinical Center (CC)
- Target Recruit Count
- 33
- Registration Number
- NCT00062036
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
- Conditions
- Sarcoma
- Interventions
- Drug: celecoxibDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: vinblastine sulfateDrug: vincristine sulfateProcedure: conventional surgeryRadiation: radiation therapyDrug: MESNADrug: Filgrastim
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT00061893
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- Myelodysplastic SyndromesLeukemiaMyelodysplastic/Myeloproliferative DiseasesLymphoma
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00062140
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Acute Undifferentiated LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: allopurinolDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: vincristine sulfateDrug: dexamethasoneDrug: asparaginaseBiological: filgrastimDrug: imatinib mesylateDrug: methotrexateDrug: cytarabineDrug: trimethoprim-sulfamethoxazoleDrug: mercaptopurineDrug: leucovorin calciumBiological: alemtuzumabDrug: acyclovirOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 302
- Registration Number
- NCT00061945
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-06-05
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00008203
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
- Conditions
- LeukemiaLymphoma
- Interventions
- First Posted Date
- 2003-05-21
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 83
- Registration Number
- NCT00005977
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Texas Oncology P.A., Dallas, Texas, United States
Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors
- Conditions
- Brain TumorsCentral Nervous System TumorsNeuroblastoma
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cisplatinDrug: cyclophosphamideDrug: vincristine sulfateProcedure: adjuvant therapyRadiation: radiation therapy
- First Posted Date
- 2003-05-19
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 168
- Registration Number
- NCT00003203
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇨🇦British Columbia Children's Hospital, Vancouver, British Columbia, Canada
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
- Conditions
- LeukemiaGraft Versus Host DiseaseMyelodysplastic Syndromes
- First Posted Date
- 2003-05-09
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Chimeric Therapies
- Registration Number
- NCT00004255
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States
🇺🇸Presbyterian-St Luke's Medical Center, Denver, Colorado, United States
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Breast CancerLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmTesticular Germ Cell TumorUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 451
- Registration Number
- NCT00060255
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 3
- Registration Number
- NCT00060385
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.